

Selective anxiolysis produced by ocinaplon, a GABA_A receptor modulator

A. Lipa*^{†‡}, P. Czobor*[†], J. Stark*[†], B. Beer*[†], E. Kostakis[§], M. Gravielle[§], S. Bandyopadhyay[§], S. J. Russek[§], T. T. Gibbs[§], D. H. Farb[§], and P. Skolnick*[†]

*DOV Pharmaceutical, Inc., 433 Hackensack Avenue, Hackensack, NJ 07601; and [§]Department of Pharmacology, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118

Communicated by John W. Daly, National Institutes of Health, Bethesda, MD, March 30, 2005 (received for review November 8, 2004)

Benzodiazepines remain widely used for the treatment of anxiety disorders despite prominent, often limiting side effects including sedation, muscle relaxation, and ataxia. A compound producing a robust anxiolytic action comparable to benzodiazepines, but lacking these limiting side effects at therapeutic doses (an anxioselective agent), would represent an important advance in the treatment of generalized anxiety disorder, and perhaps other anxiety disorders. Here we report that the pyrazolo[1,5-a]-pyrimidine, ocinaplon, exhibits an anxioselective profile in both preclinical procedures and in patients with generalized anxiety disorder, the most common of the anxiety disorders. In rats, ocinaplon produces significant muscle relaxation, ataxia, and sedation only at doses >25-fold higher than the minimum effective dose (3.1 mg/kg) in the Vogel "conflict" test. This anticonflict effect is blocked by flumazenil (Ro 15-1788), indicating that like benzodiazepines, ocinaplon produces an anxiolytic action through allosteric modulation of GABA_A receptors. Nonetheless, in eight recombinant GABA_A receptor isoforms expressed in *Xenopus* oocytes, the potency and efficacy of ocinaplon to potentiate GABA responses varied with subunit composition not only in an absolute sense, but also relative to the prototypical benzodiazepine, diazepam. In a double blind, placebo controlled clinical trial, a 2-week regimen of ocinaplon (total daily dose of 180–240 mg) produced statistically significant reductions in the Hamilton rating scale for anxiety scores. In this study, the incidence of benzodiazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ from placebo. These findings indicate that ocinaplon represents a unique approach both for the treatment and understanding of anxiety disorders.

generalized anxiety disorder | benzodiazepines

Benzodiazepines remain widely used for the treatment of anxiety disorders (1, 2) despite significant limiting side effects including sedation, muscle relaxation, and ataxia. This spectrum of pharmacological actions is produced by augmenting the actions of the inhibitory neurotransmitter GABA through an allosteric modulation of GABA_A receptors (3, 4), a family of heteropentameric, ligand-gated ion channels (5). Although there are at least seven subunit classes, the majority of GABA_A receptors are composed of α -, β -, and γ -subunits (6), with multiple subtypes of each that can assemble to form GABA-gated ion channels (5, 7). This subunit repertoire allows for remarkable receptor diversity, and >12 distinct GABA_A receptor isoforms may be present in the mammalian nervous system (8).

Benzodiazepines bind to and act upon a subset of GABA_A receptors containing β - and γ -subunits in combination with α 1-, α 2-, α 3-, or α 5-subunits. The identification of novel molecules acting at the benzodiazepine recognition site of the GABA_A receptor began >25 years ago (9, 10), and remains an area of intense interest (2, 5, 11, 12). The impetus for identifying such molecules was the discovery that the triazolopyridazine, CL 218,872 (9, 10), exhibited selectivity for "Type I" benzodiazepine receptors (subsequently identified as GABA_A receptors containing an α 1-subunit; refs. 5 and 13) and a low efficacy relative to benzodiaz-

epines in potentiating GABA-gated chloride currents (14, 15). CL 218,872 produced anxiolytic-like effects in animal models at doses substantially lower than those producing benzodiazepine-like side effects (e.g., sedation, ataxia, muscle relaxation) (16). A compound exhibiting this "anxioselective" profile in humans would represent a significant advance in the treatment and understanding of anxiety disorders.

A number of compounds have been identified that exhibit GABA_A receptor subtype selectivity and/or lower efficacy than benzodiazepines to enhance GABA-stimulated chloride currents (reviewed in ref. 2). Some compounds, such as bretazenil and abecarnil, exhibit an anxioselective profile in animals (17, 18), but data from clinical trials do not support the anxioselectivity predicted from preclinical results (19, 20). We now report that ocinaplon (DOV 273,547; 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone) fulfills both preclinical and clinical criteria for an anxioselective agent.

Methods

"Thirsty Rat" Conflict Test. The procedure used in this study was essentially as originally described by Vogel *et al.* (21). The effects of drugs or vehicle ($n \geq 8$ animals per dose) were evaluated 1 h after oral administration. See *Supporting Text*, which is published as supporting information on the PNAS web site, for further details.

Blockade of Pentylentetrazole-Induced Convulsions. The anticonvulsant properties of ocinaplon and diazepam were evaluated essentially as described (10, 22) using pentylentetrazole (19 mg/kg, i.v.) as the convulsant agent. Rats ($n \geq 4$ per dose) were challenged with pentylentetrazole 1 h after oral administration of ocinaplon, diazepam, or vehicle. See *Supporting Text* for further details.

Evaluation of Motor Function in Rats. Motor activity. One hour after oral administration of ocinaplon, diazepam, or vehicle, individual animals ($n = 12$ –24 per dose) were placed in activity chambers equipped with photoelectric cells, and activity was recorded for 5 min. The ED₅₀ was the dose that reduced activity levels to 50% in comparison with vehicle-treated control animals (10).

Inclined screen. Rats ($n \geq 8$ per dose) were placed individually on an inclined screen (60°) 1 h after oral administration of vehicle, ocinaplon, or diazepam. The number of animals remaining on the screen for at least 30 min was recorded. The ED₅₀ is the dose producing screen failures in 50% of the rats (10).

Rod walking. Rats were trained to traverse a wooden rod inclined at 17°. One hour after orally administered diazepam and ocinaplon, the number of animals ($n = 10$ per dose) unable to traverse the rod

Abbreviations: GAD, generalized anxiety disorder; HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression.

[†]A.L., P.C., J.S., B.B. and P.S. are employees of DOV Pharmaceutical, Inc. D.H.F. is a member of the Scientific Advisory Board of DOV Pharmaceutical, Inc. Part of this research was funded by a Sponsored Research Agreement between DOV Pharmaceutical, Inc., and Boston University.

[‡]To whom correspondence should be addressed. E-mail: alippa@dovpharm.com.

© 2005 by The National Academy of Sciences of the USA




Fig. 1. Anticonflict actions of ocinaplon and diazepam: blockade by flumazenil. Adult, male CD rats (Charles River Breeding Laboratories) were orally administered vehicle (0.5% methylcellulose containing 0.1% Tween 80), ocinaplon, or diazepam suspended in vehicle. Sixty minutes later, the effect of these treatments was evaluated in the "thirsty rat conflict" test, essentially as described (21). Flumazenil (12.5 mg/kg, i.p.) was administered 30 min before testing. This dose of flumazenil does not affect performance in the thirsty rat conflict test (data not shown). The minimum effective dose (the first dose producing a statistically significant difference from vehicle treated rats) of both ocinaplon and diazepam was 3.1 mg/kg. Values represent the mean ($n \geq 8$ animals per dose) increase in punished responding compared to vehicle treated rats. Open circles, ocinaplon; open squares, diazepam; filled circles, ocinaplon plus flumazenil; filled squares, diazepam plus flumazenil.

was evaluated (22). The ED_{50} was that dose causing 50% of the rats to fall. ED_{50} values were calculated by the probit analysis method of Finney (23).

Squirrel Monkey Conflict Procedure. The effects of ocinaplon, diazepam, and vehicle were evaluated in a conflict procedure (22, 24) using adult, male squirrel monkeys (*Saimiri sciureus*). Drugs or vehicle were administered by gavage 60 min before placing the animals in the operant conditioning chamber. The mean reinforced responses, mean conflict responses, and mean conflict response failures were calculated for each dosage level. Significant differences between drug responding and control level (obtained on the day before treatment) were determined by using a paired *t* test. See *Supporting Text* for further details.

Clinical Study in Generalized Anxiety Disorder. Twenty centers in Germany received Ethics Committee approval to participate in this study, with 15 centers enrolling patients. The study was performed in accordance with the declaration of Helsinki, Good Clinical Practice on Medicinal Products in the European Community, Food and Drug Administration Good Clinical Practice Regulations, and International Harmonization Good Clinical Practice Guidelines. Study-related procedures were not initiated until a subject had given written informed consent on an Institutional Review Board-approved consent form. Eligible outpatients ≥ 18 years of age who met the DSM-IV criteria for general anxiety disorder (GAD), had sufficient initial symptom severity to require treatment [total score on the Hamilton Rating Scale for Anxiety (HAM-A) ≥ 22], and did not have coexisting depressive symptoms [total score on the Hamilton Rating Scale for Depression (HAM-D) ≤ 15] were included in a placebo run-in period (single-blind, 1-week dosing). Those individuals whose HAM-A scores did not decrease by $>10\%$ during the run-in period were enrolled in a 14-day, double-blind treatment period and randomized to one of three treatment groups. In addition to the principal efficacy measure, change in the HAM-A (25), secondary measures of efficacy included the clinical global impression scale, and the patient's self-rating scale for generalized anxiety (26). Repeated weekly assessments of symptom severity over time served as the dependent variable in the analyses




Fig. 2. Effects of ocinaplon and diazepam on motor function in rats. Compounds were evaluated 60 min after oral administration. (Top) Motor activity. Values represent the mean % decrease in motor activity of 12–24 rats per dose compared to vehicle treated animals. The ED_{50} of diazepam and ocinaplon was 17.5 and 81.7 mg/kg, respectively. (Middle) Inclined screen. The effect of diazepam and ocinaplon was evaluated on the ability of rats to remain on an inclined (60°) screen for 30 min. The ED_{50} of diazepam and ocinaplon was 15.5 (3.5–24.9, 95% CI) and 172.2 (123.3–244.5, 95% CI) mg/kg, respectively. (Bottom) Rod walking. Animals were trained to traverse a rod inclined at 17°. Values represent the mean of 10 rats per dose. The ED_{50} of diazepam and ocinaplon was 13.8 (2.7–20.4, 95% CI) and 92 (68–124, 95% CI) mg/kg, respectively.

for efficacy. Adverse experiences were evaluated at baseline (i.e., end of screening/placebo run-in period) and at the beginning of every week thereafter. Each nonlaboratory adverse experience reported by the patients was rated for its severity and for its relationship with the study drug. Vital signs were evaluated by monitoring sitting blood pressure, respiratory rate, temperature, and pulse rate. Screening and safety analysis consisted of blood chemistry and liver function tests in conjunction with urinalysis and hematologic testing (complete blood count).

Inhibition of Radioligand Binding to Native GABA_A Receptors. The ability of ocinaplon to inhibit [³H]flumazenil binding to native GABA_A receptors prepared from rat cortical and cerebellar mem-




Fig. 3. Anticonflict actions of ocinaplon (Upper) and diazepam (Lower) in primates. Punished and nonpunished responding in adult, male squirrel monkeys was performed as described (24). Drugs were administered orally 60 min before a test session. A profound sedation was noted in animals administered 4 mg/kg diazepam. Although a significant reduction in nonpunished responding was observed with ocinaplon at 128 mg/kg, overt signs of sedation were not noted. Filled bars, punished (conflict) responding; open bars, unpunished responding; *, $P < 0.05$ paired t test.

branes was performed essentially as described (ref. 27; see *Supporting Text* for further details).

Evaluation of GABA-Gated Currents in Recombinant Human GABA_A Receptors Expressed in *Xenopus* Oocytes. cRNAs encoding GABA_A receptor $\alpha 1$, 2-, 3-, or 5-, $\beta 2$, and $\gamma 2$ - or 3-subunits were microinjected into *Xenopus laevis* oocytes. Forty-eight hours later, the effects of ocinaplon and diazepam were measured on GABA-gated inward currents using a Warner two-electrode voltage clamp amplifier in voltage clamp mode as described (see ref. 28 and *Supporting Text* for further details).

Animals. Studies in both rats and monkeys were conducted at Lederle Laboratories (Pearl River, NY). Protocols were approved by the Animal Care and Use Committee consistent with National Institutes of Health guidelines. Studies in *X. laevis* frogs were approved by the Animal Care and Use Committee, Boston University School of Medicine. Male CD rats (Charles River Breeding Laboratories) weighing 120–220 g were used in these experiments. Adult, male squirrel monkeys (*S. sciureus*) were obtained from a local colony. Female, oocyte-positive *X. laevis* frogs were purchased from *Xenopus* One (Ann Arbor, MI) or Nasco (Fort Atkinson, WI).

Drugs. Ocincaplon was manufactured by ACRAF SpA (Aprilia, Italy). Diazepam, flumazenil, and other reagents were obtained from Sigma/Research Biochemicals. Drugs were suspended in 0.5% methylcellulose containing 0.1% Tween 80.

Results

Preclinical Studies in Rodents and Primates. The ability of a drug to increase punished responding in “conflict” procedures is highly




Fig. 4. Anxiolytic effects of ocinaplon in GAD. Eligible patients with a diagnosis (HAM-A score of ≥ 20 at the end of the 1-week placebo run-in period) of GAD were randomized into three groups receiving placebo, 180 mg of ocinaplon (60 mg three times daily), or 240 mg of ocinaplon (120 mg twice daily) for 14 days. For each group and each time point, the depicted values represent the mean total score on the HAM-A scale of evaluable patients completing the study with no protocol deviation. The overall effect of ocinaplon on HAM-A scores was significantly different ($P = 0.007$) compared with placebo. Filled circles, placebo; open circles, ocinaplon, 180 mg/day; filled squares, ocinaplon 240 mg/day; a: $t = 1.7$, $df = 66$, $P = 0.09$ for Ocincaplon, 180 mg/day vs. placebo; b: $t = 3.1$, $df = 62$, $P = 0.003$ for Ocincaplon 240 mg/day vs. placebo. These t values represent the dose \times time interaction for each individual dose of ocinaplon.

predictive of an antianxiety effect in humans (21, 22, 29). Ocincaplon produced a dose-related increase in punished responding in a “thirsty rat” conflict procedure (21) with a potency and efficacy comparable to the prototypic benzodiazepine, diazepam (Fig. 1). The minimum effective dose for each drug was 3.1 mg/kg when administered orally 1 h before testing. The ability of flumazenil (Ro 15-1788) to antagonize the anticonflict action of ocinaplon (Fig. 1) indicates that, like benzodiazepines (30), this effect is mediated by GABA_A receptors. Furthermore, ocinaplon was as potent and effective as diazepam in reducing pentylenetetrazole-induced convulsions [ED₅₀ values of 9.6 (95% CI; range, 7.9–12.1) mg/kg and 7.5 (95% CI; range, 5.3–10.6) mg/kg orally, respectively], another preclinical test that is highly predictive of an antianxiety effect in humans (22).

Ocincaplon produced performance deficits comparable to diazepam in the motor activity, rod-walking, and inclined screen tests (Fig. 2) that are considered predictive of side effects (sedation, ataxia, and muscle relaxation, respectively) typically associated with benzodiazepines (22). However, ocinaplon was 5- to 10-fold less potent than diazepam in disrupting performance in these tests, in contrast to its potency in the thirsty rat conflict and antipentylenetetrazole tests. This differential potency of ocinaplon in rodents is consistent with the profile of an “anxiolytic” agent.

Ocincaplon produced a similar anxiolytic profile in nonhuman primates. Squirrel monkeys were trained to bar press under conditions of both reward and punishment in a conflict procedure that is sensitive to clinically effective anxiolytics (22, 24). The minimum effective dose (MED) for ocinaplon to increase punished responding was 4 mg/kg orally; a significant increase in punished responding was maintained until a dose of 64 mg/kg. At a dose of 128 mg/kg, both punished and food reinforced responding were decreased (Fig. 3). The MED for diazepam to increase punished responding in this procedure was 0.5 mg/kg. However, this anticonflict effect was no longer apparent at doses ≥ 2 mg/kg, pre-

Table 1. Summary of treatment emergent adverse events (AEs)

MedDRA system organ classification (SOC)	MedDRA preferred term	Number of patients (%)		
		Placebo (n = 42)	TID60 (n = 43)	BID120 (n = 42)
One or more AEs*	All patients with AEs	4 (9.5)	5 (11.6)	4 (9.5)
Gastrointestinal disorders	Patients with AEs	1 (2.4)	1 (2.3)	1 (2.4)
	Abdominal pain upper	1 (2.4)	0	0
	Nausea	0	1 (2.3)	1 (2.4)
General disorders and administration site conditions	Patients with AEs	1 (2.4)	1 (2.3)	1 (2.4)
	Fatigue	1 (2.4)	0	1 (2.4)
	Mucous membrane disorder NOS	0	1 (2.3)	0
Immune system disorders	Patients with AEs	0	0	1 (2.4)
	Conjunctivitis allergic	0	0	1 (2.4)
Investigations	Patients with AEs	0	1 (2.3)	0
	Heart rate increased	0	1 (2.3)	0
Musculoskeletal and connective tissue disorders	Patients with AEs	2 (4.8)	0	2 (4.8)
	Back pain	1 (2.4)	0	0
	Musculoskeletal chest pain	0	0	1 (2.4)
	Neck pain	0	0	1 (2.4)
	Torticollis	1 (2.4)	0	0
	Nervous system disorders	Patients with AEs	0	2 (4.7)
	Agitation	0	1 (2.3)	0
	Sedation	0	1 (2.3)	0
	Somnolence	0	1 (2.3)	0
	Vertigo	0	0	1 (2.4)
Renal and urinary disorders	Patients with AEs	0	1 (2.3)	0
	Cystitis NOS	0	1 (2.3)	0
Respiratory, thoracic, and mediastinal disorders	Patients with AEs	0	1 (2.3)	0
	Sinusitis NOS	0	1 (2.3)	0

Patients reporting individual AEs may not add up to the number of patients within a SOC because a subject may have reported more than one AE with in a SOC term. MedDRA, medical dictionary regulatory applications; NOS, not otherwise specified.

*No significant difference among treatments in proportion of patients with AEs.

sumably because of disruption of motor activity that also significantly reduced responding under a reinforcing (nonpunishment) schedule at a dose of 4 mg/kg (Fig. 3).

Ocinaplon in Patients with GAD. Based on these preclinical results, we initiated a multicenter, double-blind, placebo-controlled safety and efficacy study of ocinaplon in GAD. Eligible patients were enrolled in a 14-day double-blind treatment period and randomized to one of three treatment groups: placebo ($n = 42$), 60 mg of ocinaplon three times a day (TID) ($n = 43$), or 120 mg of ocinaplon twice daily (BID) ($n = 42$). The principal efficacy measure was change in the HAM-A score at the end of the 2-week study.

Hierarchical linear modeling analysis of HAM-A scores obtained from the intent-to-treat (ITT) population comprising all randomized subjects (including patients who did not complete the trial) yielded a significant interaction between time and treatment ($t = 2.6$, $P = 0.011$) for the global contrast between ocinaplon and placebo. Patients assigned to placebo displayed a mean reduction in HAM-A scores of 9.7 ± 1.4 (standard error) points ($P = 0.001$) after 2 weeks, whereas the reduction in total HAM-A scores in patients assigned to the 60-mg ocinaplon TID and 120-mg ocinaplon BID arms were 14.1 ± 1.9 and 15.3 ± 1.9 points, respectively. Analyses of the individual treatment group contrasts in the ITT population for the 2-week data demonstrated that 120-mg ocinaplon BID elicited a significantly greater reduction in symptom severity compared to placebo ($t = 2.34$, $P = 0.02$). The difference between 60-mg ocinaplon TID and placebo approached statistical significance ($t = 1.89$, $P = 0.06$). Investigation of the effect size estimates indicated that the two doses were essentially identical in efficacy (with slight numerical advantage for 120-mg ocinaplon BID compared to 60-mg ocinaplon TID). An analysis of the set of patients completing the study with no protocol deviation ($n = 32$,

35, and 31 for placebo, 180 mg of ocinaplon, and 240 mg of ocinaplon, respectively) yielded results (Fig. 4) essentially identical to those found in the ITT sample. A statistically significant difference in HAM-A scores for the global contrast between ocinaplon and placebo was observed as early as 1 week ($P = 0.022$) after the start of dosing. Statistically significant dose \times time interactions were also observed for each individual dose of ocinaplon ($t = 1.7$, $df = 66$, $P = 0.09$ for 180 mg/day ocinaplon vs. placebo; $t = 3.1$, $df = 62$, $P = 0.003$ for 240 mg/day ocinaplon) compared to placebo. The reductions in HAM-A scores produced by ocinaplon were paralleled by changes in both the clinical global impression and self-rating scale measures (data not shown).

There were no treatment-emergent, serious adverse events in this trial. The number of patients in each group with at least one treatment emergent adverse event in the trial was relatively low (Table 1), and the proportion of patients with treatment emergent adverse events was comparable among treatment groups (placebo, 9.5%; 240 mg of ocinaplon, 9.5%; 180 mg of ocinaplon, 11.6%; $P = 1.0$, Fisher's exact test). No clinically significant, treatment-emergent laboratory abnormalities were detected in the study population. In general, the overall side-effect profile was unremarkable across the entire study population. Of particular note was an absence of significant findings or trends for the central nervous system and other effects normally associated with benzodiazepines such as sedation and dizziness (Table 1 and refs. 31 and 32).

In Vitro Studies: Native and Recombinant GABA_A Receptors. Ocinaplon selectively inhibited [³H]flunitrazepam binding in a broad receptor-binding screen using 30 different ligands (data not shown), consistent with the observation that Ro 15-1788 antagonizes the anticonflict actions of ocinaplon (Fig. 1). Ocinaplon was ≈ 3 -fold more potent in inhibiting [³H]flunitrazepam binding to rat cere-

bellum than cortex (IC_{50} values of 1.2 μ M and 3.8 μ M, respectively, with Hill coefficients 0.9 and 0.7 in cerebellum and cortex, respectively). These radioligand-binding data indicate that compared to diazepam, the prototypic benzodiazepine, ocinaplon is a low-affinity ligand at GABA_A receptors that exhibits a modest selectivity for GABA_{A1} receptors (receptors containing α 1-subunits; ref. 5), because this subunit is enriched in cerebellum compared to cortex (6, 33, 34).

To determine how subunit composition influences the molecular actions of ocinaplon at GABA_A receptors, cRNAs corresponding to specific combinations of α 1, 2-, 3-, or 5-, β 2, and γ 2- or 3-subunits were subcloned and microinjected into *X. laevis* oocytes. Forty-eight hours later, the effects of ocinaplon and diazepam were measured on GABA-gated inward currents in the voltage clamp mode (28). Both the potency and efficacy (that is, the maximal effect) of diazepam to potentiate GABA-stimulated chloride currents varied with subunit composition (Fig. 5 and Table 2). Likewise, the potency and efficacy of ocinaplon varied with subunit composition (see Fig. 5 and Table 2), not only in an absolute sense but also relative to diazepam. Thus, ocinaplon increased GABA-stimulated chloride currents with efficacies ranging from \approx 25% to 85% relative to diazepam, and potencies 5- to 35-fold lower than diazepam across these eight recombinant receptor isoforms. The greatest relative potentiation of GABA-stimulated currents was produced in receptors containing the α 1-subunit. In those cells containing the α 1 β 2 γ 2 isoform where ocinaplon displayed the greatest relative efficacy, diazepam was approximately eight times more potent than ocinaplon in its ability to potentiate GABA-stimulated currents (see Table 2), a relative potency comparable to that seen in the squirrel monkey conflict procedure (Fig. 3). The substitution of a γ 3-subunit in this α 1-containing complex reduced the relative efficacy of ocinaplon with only a small increase in relative potency. Similar substitution of a γ 3-subunit in the α 2-, α 3-, and α 5-containing complexes produced larger increases in the relative potency of ocinaplon while decreasing its relative efficacy (Table 2). Ocincaplon may thus be viewed as a partial positive modulator at α 2-, α 3-, and α 5-containing receptors because its efficacy was substantially lower than diazepam at these receptor isoforms (Table 2).

Discussion

Ocinaplon is anxiolytic in rodents and primates, including humans, with a magnitude of effect comparable to benzodiazepines. Thus, in “conflict” procedures that are predictive of anxiolytic activity (22), ocinaplon produced a maximum response comparable to the prototypic benzodiazepine diazepam (Figs. 1 and 3). In GAD patients, the difference from placebo in the HAM-A score (4.4–5.6 points) in both ocinaplon dose groups (180- and 240-mg total daily dose) after 2 weeks of treatment (Fig. 4) was comparable to the difference (5.1 points) recently reported after 4 weeks of treatment with the benzodiazepine, lorazepam (6-mg total daily dose) (32). However, in contrast to the side effect profile typically produced by anxiolytic doses of benzodiazepines (e.g., a high incidence of patients experiencing somnolence, dizziness, and incoordination) (32), the incidence of adverse events with ocinaplon was not different from placebo (Table 1). Additional multicenter studies of longer duration are in progress to confirm both the efficacy of ocinaplon in reducing the symptoms of GAD and its apparent anxioselective profile.

Previously published results using genetically modified “knock-in” mice have emphasized α 2-containing receptor isoforms as critical for mediating the anxiolytic effects of benzodiazepines, and α 1-containing isoforms as important for mediating the sedative effects (35, 36). Thus, at face value, the present results are at variance with these previously reported data because ocinaplon was most potent and efficacious, both in an absolute sense and relative to diazepam, in receptors containing α 1-subunits. Several different interpretations might explain this apparent inconsistency.




Fig. 5. Potentiation of GABA-gated currents by ocinaplon and diazepam in recombinant rat GABA_A receptors expressed in *Xenopus* oocytes. Potentiation was determined by using an EC₁₀ concentration of GABA. Curves were fitted by using nonlinear regression analysis and represent the mean values obtained from at least five oocytes harvested from at least two batches. Open circles, diazepam; filled circles, ocinaplon.

First, it is possible that ocinaplon and benzodiazepines act on different GABA_A receptor subtypes such that ocinaplon produces its anxiolytic effects through actions on α 1-containing complexes, whereas benzodiazepines and perhaps other structural classes of compounds (11, 12) produce anxiolytic effects through actions on α 2-containing (GABA_{A2}) receptors. This hypothesis is presently

Table 2. Potencies and efficacies of diazepam and ocinaplon in recombinant GABA_A receptors

Receptor composition	Diazepam (Dz)			Ocinaplon (Ocin)			Ocin/Dz	
	<i>E</i> _{max} , % potentiation	<i>EC</i> ₅₀ , μM	p <i>EC</i> ₅₀	<i>E</i> _{max} , % potentiation	<i>EC</i> ₅₀ , μM	p <i>EC</i> ₅₀	<i>EC</i> ₅₀	<i>E</i> _{max}
α1β2γ25	103 ± 8.4	0.36	6.45 ± 0.06	88 ± 8.6	3.07	5.51 ± 0.14	8.6	0.85
α1β2γ3	90 ± 8.0	1.95	5.71 ± 0.06	51 ± 3.5	10.03	5.00 ± 0.05	5.1	0.57
α2β2γ25	108 ± 13.5	0.16	6.81 ± 0.06	52 ± 8.8	3.39	5.47 ± 0.07	21.9	0.48
α2β2γ3	127 ± 4.2	0.78	6.11 ± 0.02	46 ± 5.2	3.83	5.42 ± 0.04	4.9	0.36
α3β2γ25	159 ± 16.9	0.20	6.71 ± 0.14	78 ± 7.1	4.59	5.34 ± 0.06	23.5	0.49
α3β2γ3	166 ± 14.8	1.58	5.80 ± 0.04	41 ± 4.5	9.02	5.05 ± 0.05	5.7	0.25
α5β2γ25	154 ± 8.0	0.11	6.96 ± 0.07	61 ± 4.2	3.79	5.42 ± 0.07	34.8	0.40
α5β2γ3	74 ± 9.9	1.36	5.87 ± 0.03	22 ± 0.2	7.40	5.13 ± 0.05	5.4	0.30

under investigation in selectively bred “knock-in” mice expressing either GABA_{A1} or GABA_{A2} receptors that are insensitive to benzodiazepines (35–37). Second, it is possible that only partial activation of α2-containing GABA_A receptors by ocinaplon is sufficient to produce a full anxiolytic effect. The low efficacy of L-838,417 (which exhibits an anxiolytic profile in animals) relative to benzodiazepines at α2-containing receptors is consistent with this hypothesis (12, 36). However, this hypothesis does not adequately explain the anxiolytic property of ocinaplon, given its potency and efficacy at α1-containing receptors, which are presumed to mediate the sedative effects of benzodiazepines. A variation of this hypothesis posits that anxiolysis requires that a compound produce only partial activation, whereas “side effects” require full activation of GABA_A receptors relative to a benzodiazepine. However, this hypothesis may also be viewed as flawed because ocinaplon, despite its partial agonist profile at α2-, α3-, and α5-containing receptors (Fig. 5 and Table 2), produces sedation, muscle relaxation, and ataxia, albeit at doses more than one order of magnitude higher than those producing an anxiolytic effect. Rather, a combination of high relative potency and high relative

efficacy at certain receptor subtypes would seem to more parsimoniously explain its anxiolytic properties. Finally, although studies using knock-in mice indicate that GABA_{A1} receptors contribute to the sedative and anticonvulsant properties of benzodiazepines (36, 37), pharmacological studies using a selective GABA_{A1} antagonist (38, 39) indicate that the anticonflict (but not the motor impairing) actions of diazepam (11, 40) are mediated via GABA_{A1} receptors. There are other significant inconsistencies between data obtained in knock-in mice and pharmacological studies using subtype selective pharmacological agents in wild type animals (41). It is not known whether such differences relate to the behavioral assays used, species differences, or a combination of these factors. Furthermore, given both the array of symptoms associated with GAD and the potential for GABA_A receptor heterogeneity, ocinaplon may activate multiple GABA_A receptor isoforms, including those not examined in the present study, to produce an anxiolytic action in the clinic. The present results demonstrate ocinaplon represents both a significant advance in the treatment of generalized anxiety disorder and a unique tool for studying the molecular substrates of anxiety.

1. Stahl, S. M. (2002) *J. Clin. Psychiatry* **63**, 756–757.
2. Atack, J. R. (2003) *Curr. Drug Target CNS Neurol. Disord.* **2**, 213–232.
3. Choi, D. W., Farb, D. H. & Fischbach, G. D. (1977) *Nature* **269**, 342–344.
4. Haefely, W. & Polc, P. (1986) in *Benzodiazepine/GABA Receptors and Chloride Channels*, eds. Olsen, R. W. & Venter, C. (Liss, New York), pp. 97–133.
5. Barnard, E. A., Skolnick, P., Olsen, R. W., Mohler, H., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A. N. & Langer, S. Z. (1998) *Pharmacol. Rev.* **50**, 291–313.
6. De Blas, A. L. (1996) *Mol. Neurobiol.* **12**, 55–71.
7. Korpi, E. R., Grunder, G. & Luddens, H. (2002) *Prog. Neurobiol.* **67**, 113–159.
8. McKernan, R. M. & Whiting, P. J. (1996) *Trends Neurosci.* **19**, 139–143.
9. Lippa, A. S., Critchett, D., Sano, M. C., Klepner, C. A., Greenblatt, E. N., Coupet, J. & Beer, B. (1979) *Pharmacol. Biochem. Behav.* **10**, 831–843.
10. Lippa, A. S., Coupet, J., Greenblatt, E. N., Klepner, C. A. & Beer, B. (1979) *Pharmacol. Biochem. Behav.* **11**, 99–106.
11. Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Francon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) *J. Pharmacol. Exp. Ther.* **298**, 753–768.
12. Johnstone, T. B., Hogenkamp, D. J., Coyne, L., Su, J., Halliwell, R. F., Tran, M. B., Yoshimura, R. F., Li, W. Y., Wang, J. & Gee, K. W. (2004) *Nat. Med.* **10**, 31–32.
13. Pritchett, D. B., Luddens, H. & Seeburg, P. H. (1989) *Science* **245**, 1389–1392.
14. Chan, C. Y. & Farb, D. H. (1985) *J. Neurosci.* **5**, 2365–2373.
15. Wafford, K. A., Whiting, P. J. & Kemp, J. A. (1993) *Mol. Pharmacol.* **43**, 240–244.
16. Lippa, A. S., Meyerson, L. R. & Beer, B. (1982) *Life Sci.* **31**, 1409–1417.
17. Haefely, W., Martin, J. R. & Schoch, P. (1990) *Trends Pharmacol. Sci.* **11**, 452–456.
18. Stephens, D. N., Turski, L., Hillman, M., Turner, J. D., Schneider, H. H. & Yamaguchi, M. (1992) *Adv. Biochem. Psychopharmacol.* **47**, 395–405.
19. Ballenger, J. C., McDonald, S., Noyes, R., Rickels, K., Sussman, N., Woods, S., Patin, J. & Singer, J. (1991) *Psychopharmacol. Bull.* **27**, 171–179.
20. van Steveninck, A. L., Gieschke, R., Schoemaker, R. C., Roncari, G., Tuk, B., Pieters, M. S., Breimer, D. D. & Cohen, A. F. (1996) *Br. J. Clin. Pharmacol.* **41**, 565–573.
21. Vogel, J. R., Beer, B. & Clody, D. E. (1971) *Psychopharmacologia* **21**, 1–7.
22. Lippa, A., Nash, P. A. & Greenblatt, D. J. (1979) in *Anxiolytics: Industrial Pharmacology*, eds. Fielding, S. & Lal, H. (Futura, Mount Kisco, NY), Vol. 3, pp. 41–81.
23. Finney, D. J. (1978) *Statistical Methods in Biological Assay* (Hafner, New York).
24. Greenblatt, E. N., Lippa, A. S. & Osterberg, A. C. (1978) *Arch. Int. Pharmacodyn. Ther.* **233**, 107–135.
25. Hamilton, M. (1959) *Br. J. Med. Psychol.* **23**, 50–55.
26. Guy, W. (1976) *ECDEU Assessment Manual for Psychopharmacology* (National Institute of Mental Health, Rockville, MD), revised edition.
27. Liu, R., Hu, R. J., Zhang, P., Skolnick, P. & Cook, J. M. (1996) *J. Med. Chem.* **39**, 1928–1934.
28. Park-Chung, M., Malayev, A., Purdy, R. H., Gibbs, T. T. & Farb, D. H. (1999) *Brain Res.* **830**, 72–87.
29. Millan, M. J. & Brocco, M. (2003) *Eur. J. Pharmacol.* **463**, 67–96.
30. Hunkeler, W., Mohler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R. & Haefely, W. (1981) *Nature* **290**, 514–516.
31. Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M. & Pande, A. C. (2003) *J. Clin. Psychopharmacol.* **23**, 240–249.
32. Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. & Liu-Dumaw, M. (2003) *Am. J. Psychiatry* **160**, 533–540.
33. Luddens, H. & Wisden, W. (1991) *Trends Pharmacol. Sci.* **12**, 49–51.
34. Wisden, W., Laurie, D. J., Monyer, H. & Seeburg, P. H. (1992) *J. Neurosci.* **12**, 1040–1062.
35. Low, K., Crestani, F., Keist, R., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Rulicke, T., Bluethmann, H., Mohler, H. & Rudolph, U. (2000) *Science* **290**, 131–134.
36. McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) *Nat. Neurosci.* **3**, 587–592.
37. Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Martin, J. R., Bluethmann, H. & Mohler, H. (1999) *Nature* **401**, 796–800.
38. Cox, E. D., Hagen, T. J., McKernan, R. M. & Cook, J. M. (1995) *Med. Chem. Res.* **5**, 710–718.
39. Harvey, S. C., Foster, K. L., McKay, P. F., Carroll, M. R., Seyoum, R., Woods, J. E., Jr., Grey, C., Jones, C. M., McCane, S., Cummings, R., et al. (2002) *J. Neurosci.* **22**, 3765–3775.
40. Shannon, H. E., Guzman, F. & Cook, J. M. (1984) *Life Sci.* **35**, 2227–2236.
41. Rosahl, T. W. (2003) *Curr. Drug Target CNS Neurol. Disord.* **2**, 207–212.